Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPA3 | P15088 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.70 |
| ▸ | CPA1 | P15085 | 2/20 | 0.67 |
| ▸ | CPB1 | P15086 | 1/20 | 0.67 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.67 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.64 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.61 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.56 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.56 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29088272 | 1.00 | CPA3 (1.00) | CPA3CYP1A2CPA1CPB1CPB2 | |
| SCHEMBL17537902 | 0.92 | CPA3 (0.85) | CPA3CYP1A2CPA1CPB1CPB2 | |
| SCHEMBL3174797 | 0.89 | CPA3 (0.80) | CPA3CYP1A2CPA1CPB1CPB2 | |
| SCHEMBL12494537 | 0.89 | CPA3 (0.80) | CPA3CYP1A2CPA1CPB1CPB2 | |
| SCHEMBL12494233 | 0.88 | CYP1A2 (0.83) | CPA3CYP1A2CPA1CPB1CPB2 | |
| SCHEMBL19821208 | 0.88 | CYP1A2 (0.83) | CPA3CYP1A2CPA1CPB1CPB2 | |
| SCHEMBL6724759 | 0.88 | CYP1A2 (0.83) | CPA3CYP1A2CPA1CPB1CPB2 | |
| SCHEMBL26679347 | 0.87 | CPA3 (0.77) | CPA3CYP1A2CPA1CPB1CPB2 | |
| SCHEMBL11143841 | 0.86 | CPA3 (0.75) | CPA3CYP1A2CPA1CPB1CPB2 | |
| SCHEMBL31303730 | 0.86 | CPA3 (0.75) | CPA3CYP1A2CPA1CPB1CPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115570263-A | Laser control structure and laser bonding method using the same | 韩国电子通信研究院 | 2023-01-06 | — | — | CN | claimed |
| US-20220402070-A1 | LASER CONTROL STRUCTURE AND LASER BONDING METHOD USING THE SAME | ELECTRONICS AND TELECOMMUNICATIONS RESEARCH INSTITUTE (KR) | 2022-12-22 | — | — | US | claimed |
| EP-4534092-B1 | COMPOSITIONS AND METHODS FOR MODULATING PKK EXPRESSION | IONIS PHARMACEUTICALS INC (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-4711459-A2 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | Ionis Pharmaceuticals, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20260035695-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION | IONIS PHARMACEUTICALS INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260022382-A1 | Compositions and Methods for Modulating Complement Factor B Expression | IONIS PHARMACEUTICALS, INC. (US) | 2026-01-22 | — | — | US | disclosed |
| US-12516319-B2 | Compositions and methods for modulating TTR expression | IONIS PHARMACEUTICALS, INC. (US) | 2026-01-06 | — | — | US | disclosed |
| US-12509684-B2 | Compositions and methods for modulating apolipoprotein C-III expression | IONIS PHARMACEUTICALS, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-20250346899-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | IONIS PHARMACEUTICALS, INC. (US) | 2025-11-13 | — | — | US | disclosed |
| US-12291709-B2 | Compositions and methods for modulating apolipoprotein (a) expression | IONIS PHARMACEUTICALS, INC. (US) | 2025-05-06 | — | — | US | disclosed |
| US-12290567-B2 | Asialoglycoprotein Receptor mediated delivery of therapeutically active conjugates | ARCTURUS THERAPEUTICS, INC. (US) | 2025-05-06 | — | — | US | disclosed |
| EP-1363876-A1 | GLUCOCORTICOID RECEPTOR MODULATORS | Abbott Laboratories (US) | 2003-11-26 | — | — | EP | disclosed |
| US-6583180-B2 | Antidiabetic agents | ABBOTT LABORATORIES | 2003-06-24 | — | — | US | disclosed |
| US-20020156311-A1 | Glucocorticoid receptor modulators | KARO BIO AB (SE) | 2002-10-24 | — | — | US | disclosed |
| WO-2002064550-A1 | GLUCOCORTICOID RECEPTOR MODULATORS | ABBOTT LABORATORIES (US) | 2002-08-22 | — | — | WO | disclosed |
| WO-1997049711-A1 | DERIVATIVES OF CARBOXY GEM-BISPHOSPHONATES WITH ANTITUMOR ACTIVITY, A PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) | 1997-12-31 | — | — | WO | disclosed |
| US-4154937-A | ANGIOTENSIN CONVERTING ENZYME INHIBITORS | E. R. SQUIBB & SONS, INC. (US) | 1979-05-15 | — | — | US | disclosed |
| US-4128653-A | Reduction of blood pressure with carboxyalkylacyl-pipecolic acid derivatives | E. R. SQUIBB & SONS, INC. (US) | 1978-12-05 | — | — | US | disclosed |
| US-4086338-A | HYPOTENSIVE AGENTS, ANGIOTENSIN CONVERTING ENZYME INHIBITORS | E. R. SQUIBB & SONS, INC. (US) | 1978-04-25 | — | — | US | disclosed |
| US-4052511-A | ANGIOTENSIN CONVERTING ENZYME INHIBITORS | E. R. SQUIBB & SONS, INC. (US) | 1977-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035695-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION | APOL1, APOB, PCSK9 | CPA3 611/4885CYP1A2 3894/4885CPA1 694/4885 |
| US-12290567-B2 | Asialoglycoprotein Receptor mediated delivery of therapeutically active conjugates | ASGR1, FCGR2A, FCGR3B | CPA3 618/4885CYP1A2 3138/4885CPA1 803/4885 |
| US-20260022382-A1 | Compositions and Methods for Modulating Complement Factor B Expression | CFB, CFH, C5 | CPA3 1275/4885CYP1A2 4296/4885CPA1 753/4885 |
| US-20020156311-A1 | Glucocorticoid receptor modulators | NR3C1, NR5A1, NR3C2 | CPA3 4073/4885CYP1A2 469/4885CPA1 2955/4885 |
| US-12509684-B2 | Compositions and methods for modulating apolipoprotein C-III expression | APOB, APOL1, NSUN2 | CPA3 1448/4885CYP1A2 4422/4885CPA1 1681/4885 |
| US-12291709-B2 | Compositions and methods for modulating apolipoprotein (a) expression | APOB, APOL1, LDLR | CPA3 1418/4885CYP1A2 2871/4885CPA1 542/4885 |
| US-20250346899-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | CSGALNACT1, GALNT1, GALNT6 | CPA3 3397/4885CYP1A2 4804/4885CPA1 2288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.